Skyhawk Therapeutics announces 12-month results from its Phase 1/2 clinical trial of SKY-0515 in people with Huntington’s disease. The company reports “favorable and consistent trends” for participants receiving SKY-0515 across all four cUHDRS subcomponents it highlights: Total Functional Capacity (TFC), Total Motor Score (TMS), Symbol Digit Modalities Test (SDMT), and the Stroop Word Reading Test (SWRT). The announcement characterizes these findings as consistent over the 12-month period and states that the reported outcomes cover both functional and motor measures as well as cognitive-related tasks included in the cUHDRS framework.
The provided source text does not include specific numerical results, statistical measures, comparator group details, safety outcomes, or subgroup analyses. It also does not clarify whether the trial is randomized, blinded, or placebo-controlled. Overall, the company’s update focuses on the trajectory of cUHDRS subcomponent results at the 12-month time point for the treatment arm.
